Astrazeneca (AZN) FCF Payout Ratio (QoQ) (2009 - 2026)
Astrazeneca (AZN) FCF Payout Ratio (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Astrazeneca | 67.83 Bn | 59.89 Bn | 12.61 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.15% |
| Dec 31, 2025 | 7.67% |
| Sep 30, 2025 | -15,375.93% |
| Jun 30, 2025 | 99.81% |
| Mar 31, 2025 | -164.70% |
| Dec 31, 2024 | 22.01% |
| Sep 30, 2024 | -8,392.48% |
| Jun 30, 2024 | 99.39% |
| Jun 30, 2023 | 99.34% |
| Mar 31, 2022 | -67.47% |
| Dec 31, 2021 | -51.85% |
| Mar 31, 2013 | 14.24% |
| Dec 31, 2012 | -229.99% |
| Mar 31, 2012 | 46.09% |
| Dec 31, 2011 | -622.27% |
| Mar 31, 2011 | 4.47% |
| Dec 31, 2010 | -176.93% |
| Mar 31, 2010 | -819.02% |
| Dec 31, 2009 | 63.57% |